Detection of circulating immunosuppressive cytokines in malignant pleural mesothelioma patients for prognostic stratification.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Elsevier Science Ltd Country of Publication: England NLM ID: 9005353 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1096-0023 (Electronic) Linking ISSN: 10434666 NLM ISO Abbreviation: Cytokine Subsets: MEDLINE
    • Publication Information:
      Publication: <2001- > : Oxford : Elsevier Science Ltd.
      Original Publication: [Philadelphia, PA] : Saunders Scientific Publications, W.B. Saunders, [c1989-
    • Subject Terms:
      Immunosuppression Therapy*; Cytokines/*blood ; Cytokines/*immunology ; Mesothelioma, Malignant/*blood ; Mesothelioma, Malignant/*immunology ; Pleural Neoplasms/*blood ; Pleural Neoplasms/*immunology; Adult ; Aged ; Aged, 80 and over ; Biomarkers, Tumor/blood ; Humans ; Kaplan-Meier Estimate ; Mesothelioma, Malignant/drug therapy ; Middle Aged ; Monocytes/metabolism ; Pleural Neoplasms/drug therapy ; Prognosis ; Treatment Outcome
    • Abstract:
      Background: No data on circulating biomarkers for the prognostic stratification of Malignant Pleural Mesothelioma (MPM) patients are available. We prospectively explored the prognostic role of circulating monocyte and cytokine levels and their dynamic change during chemotherapy.
      Patients and Methods: MPM patients receiving a first line treatment based on a platinum compound plus pemetrexed were eligible. Blood samples were collected at the baseline and at the end of induction chemotherapy. CCL-2, IL-10 and TGF-β levels in plasma were quantified by Enzyme-Linked Immunosorbent Assay (ELISA); white blood cells, monocytes and platelets were evaluated by blood count test.
      Results: Thirty-one patients were included in the study. Median overall survival (OS) was 12.13 months versus 9.6 months in patients with lower and higher monocytes count, respectively (p value = 0.02). We further stratified patients according to a combined score based on the association of IL-10, TGF-β levels and monocytes count. High combined score was associated with shorter OS and PFS in univariate and multivariate analysis. Chemotherapy induced an increase in monocytes, IL-10, but not TGF-β levels.
      Conclusion: The prognostic value of circulating levels of multiple immunosuppressive cytokines and inflammatory cells should be confirmed in a wider validation set of MPM patients.
      (Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
    • Contributed Indexing:
      Keywords: IL-10; Inflammation; Mesothelioma; Monocytes; Prognosis; TGF-β
    • Accession Number:
      0 (Biomarkers, Tumor)
      0 (Cytokines)
    • Publication Date:
      Date Created: 20210621 Date Completed: 20220216 Latest Revision: 20220216
    • Publication Date:
      20221213
    • Accession Number:
      10.1016/j.cyto.2021.155622
    • Accession Number:
      34153874